Rivaroxaban contains Not Less Than 98.0% w/w and Not More Than 102.0% w/w of C19H18ClN3O5S, calculated on the anhydrous basis.

共有 1 個藥物證書使用此成份

利伐抑凝因
Rivaroxaban

• 申請商: 龍大生技股份有限公司
• 適應症: 抗凝血劑。
• 發證日期: 2021-12-28